ClinicalTrials.gg
CompletedNCT05064358DREAMM 14Updated May 5, 2026Results posted

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 2 interventional study of Belantamab mafodotin in Multiple Myeloma, sponsored by GlaxoSmithKline. Completed at 77 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
7th of 49
177 · median 50
Started
2022
with 9 others
Phase 2
12 of 49
7 open now
Registered
22nd of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 7th largest by enrollment, is one of 10 that started in 2022, is one of 12 in phase 2, and was the 22nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Antibody drug conjugate
  • Belantamab mafodotin
  • BLENREP
  • DREAMM14
  • GSK2857916
  • Alternative dosing
  • Relapsed or refractory multiple myeloma
  • RRMM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 years of age inclusive at the time of signing the form (ICF).
  • (ECOG) performance status of 0 to 2.
  • or cytologically confirmed diagnosis of MM and a. Has undergone stem cell transplant or is considered transplant ineligible, and b. Has failed at least 3 prior lines of anti-myeloma therapies, including an anti-cluster of differentiation (CD)38 antibody (e.g., daratumumab) alone or in combination and is to an immunomodulatory agent (e.g., lenalidomide, pomalidomide) and a proteasome inhibitor (e.g., bortezomib, ixazomib, carfilzomib).
  • France specific: participants have failed at least 4 prior lines of anti-myeloma therapies
  • Participant has per modified IMWG criteria.
  • of at least 6 months, in the opinion of the investigator.
  • Male and female participants agree to abide by protocol-defined requirements.
  • Participant is capable of giving signed informed consent.
  • Participant meets country-specific inclusion criteria described in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes), or active plasma cell leukemia at the time of screening.
  • Current corneal epithelial disease, except nonconfluent superficial punctate keratitis (SPK).
  • Evidence of active mucosal or internal bleeding.
  • Presence of an active renal condition.
  • Any serious and/or unstable pre-existing medical condition, psychiatric disorder, or other conditions that could interfere with the participant's safety, obtaining , or compliance with the study procedures.
  • other than the disease under study, except for any other malignancy from which the participant has been disease free for >2 years and, will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy (MM). Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction.
  • Evidence of cardiovascular risk as per the protocol criteria.
  • Pregnant or lactating female.
  • Active infection requiring antibiotic, antiviral, or antifungal treatment.
  • Known (HIV) infection, unless the criteria in protocol can be met.
  • and C will be excluded unless the criteria in protocol can be met.
  • Cirrhosis or current unstable liver or biliary disease.
  • (ALT) >2.5× (ULN).
  • Total >1.5×ULN.
  • Systemic anti-MM therapy within \<=14 days or 5 half-lives, whichever is shorter.
  • Systemic therapy with high dose within \<=14 days before the first dose of study treatment.
  • Prior allogenic stem cell transplant.
  • Prior treatment with a monoclonal antibody \<=30 days before the first dose of study treatment. Use of monoclonal antibodies for serious conditions unrelated to multiple myeloma, such as COVID, may be permitted.
  • Prior treatment with an anti-B cell maturation antigen (BCMA) targeted therapy or reactions to any components of the study treatment.
  • Treatment with an antibody-drug conjugate.
  • Participant has received any major surgery \<=4 weeks before the first dose of study treatment. An exception may be allowed for bone stabilizing surgery.
  • Inadequate bone marrow reserve or organ functions as demonstrated by any of the following: a. \<1.0×10\^9/L, b. \<8 gram/deciliter (g/dL), c. count \<50×10\^9/L, d. Spot urine (albumin/creatinine ratio) >500 milligram/gram (mg/g), e. Estimated (eGFR) \<30 milliliter per minute per 1.73 meter square (mL/min/1.73m\^2).
  • UK specific: a. Absolute neutrophil count \<1.5×10\^9/L, c. Platelet count \<75×10\^9/L
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    Cohort 1: Participants receiving belantamab mafodotin at dose level (DL) 1

    Drug: Belantamab mafodotin

  • Experimental
    Cohort 2: Participants receiving belantamab mafodotin at DL 2

    Drug: Belantamab mafodotin

  • Experimental
    Cohort 3: Participants receiving belantamab mafodotin at DL 3

    Drug: Belantamab mafodotin

  • Experimental
    Cohort 4: Participants receiving belantamab mafodotin at DL 4

    Drug: Belantamab mafodotin

  • Experimental
    Cohort 5: Participants receiving belantamab mafodotin at DL4 with alternative dose modification

    Drug: Belantamab mafodotin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale

    The KVA scale is based on the evaluation of corneal changes using slit lamp examination. This scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.

    Time frame: Up to 29.5 months

Secondary outcomes

  1. Number of Participants With Corneal Events up to Week 16

    The number of participants with corneal events were assessed using KVA scale. The KVA scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.

    Time frame: Up to week 16

  2. Incidence Rate of Corneal Events by Grade (KVA Scale)

    Incidence rate of corneal events is defined as the percentage of participants with corneal events by grade according to the KVA scale. The KVA scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.

    Time frame: Up to 152 weeks

  3. Exposure Adjusted Incidence Rate of Corneal Events as Per CTCAE Grade

    Exposure adjusted incidence rate of corneal events is defined as the number of participants with corneal events divided by the total exposure time for all participants at risk in the treatment group. Incidence rate for corneal events was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity. The number of participants with Grades 3,4, and 5 are presented.

    Time frame: Up to 152 weeks

  4. Median Duration of All the Dose Delays

    Median duration of dose delays is defined as the median duration in time of all the dose delays in the respective treatment group. Duration of delays is defined as period from the expected start date of dose to actual start date of current dose.

    Time frame: Up to 152 weeks

  5. Percentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Corneal Events

    The percentage of participants that required dose reduction, dose interruption/delay, permanent treatment discontinuation due to corneal events were evaluated using KVA Scale. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.

    Time frame: Up to 152 weeks

  6. Cumulative Incidence of Grade 2 or Above Corneal Events (KVA Scale)

    Cumulative incidence of Grade 2 or above corneal events is defined as the percentage of corneal events of Grade 2 or above, as assessed using the KVA scale, within a specific time interval. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.

    Time frame: At 3 months, 6 months, 9 months and 12 months

  7. Toxicity Index (TI)

    Toxicity Index is a composite score derived from the severity grades of adverse events (AEs) reported during the study, based on the Common Terminology Criteria for Adverse Events (CTCAE). A participant's score is calculated as a function of the ordered toxicity grades, represented in descending order by sequence, on a scale of 0-6, where 0 represents no toxicity and 6 represents the highest toxicity. CTCAE grades are defined as follows: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe or medically significant but not immediately life-threatening), Grade 4 (Life-threatening consequences), and Grade 5 (Death related to AE). Higher grades indicate greater toxicity severity.

    Time frame: Up to 152 weeks

  8. Duration of Corneal Events of Grade 2 or Above

    Duration of corneal events is defined for each participant as the sum of duration of all the corneal AEs. The duration is defined as time from onset of any corneal events (KVA scale) of Grade 2 or above to the first time resolution to baseline, Grade 1 or below. It required at least one day gap between the resolution of all events from first occurrence to the onset of next occurrence.

    Time frame: Up to 152 weeks

  9. Percentage of Time on Study With Grade 2 or Above Corneal Events

    It is defined as the percentage of time that a participant has corneal events out of the total time that a participant is on the study. Time with corneal events is defined as time from onset of any corneal events (KVA scale) of Grade 2 or above to the first-time resolution to baseline, Grade 1 or below.

    Time frame: Up to 152 weeks

  10. Number of Participants With Change in Best Corrected Visual Acuity Test (BCVA) Scores

    Change in BCVA is defined as change in logarithm of the minimum angle of resolution (logMAR) units compared with baseline or the first visit after the cataract surgery. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any change from baseline categories is presented for right and left eyes. No change/improved vision is defined as a change from baseline \<0.1; a possible worsened vision is defined as a change from baseline \>=0.1 to \<=0.3; a definite worsened vision is defined as a change from baseline \>0.3 logMAR score. Improvement in BCVA is represented by a reduction in logMAR score from baseline, while worsening in BCVA is represented by an increase in logMAR score from baseline.

    Time frame: Baseline (Day 1) and up to 152 weeks

  11. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

    Time frame: Up to 152 weeks

  12. Percentage of Participants With a Confirmed VGPR or Better (i.e., VGPR, CR, and sCR)

    Percentage of participants with a confirmed VGPR or better defined as percentage of participant with confirmed VGPR, CR, and sCR, according to the 2016 IMWG response criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h.

    Time frame: Up to 152 weeks

  13. Time to Response (TTR)

    TTR defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better), according to the 2016 IMWG response criteria. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

    Time frame: Up to 152 weeks

  14. Duration of Response (DoR)

    DoR defined as the time from first documented evidence of PR or better until disease progression (PD) among responders according to the 2016 IMWG response criteria or death due to any cause. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).

    Time frame: Up to 152 weeks

  15. Time to Progression (TTP)

    TTP defined as the time from randomization until the earliest date of documented PD or death due to PD, according to the 2016 IMWG response criteria. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).

    Time frame: Up to 152 weeks

  16. Progression Free Survival (PFS)

    PFS defined as the time from randomization until the earliest date of documented PD, according to the 2016 IMWG response criteria, or death due to any cause. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).

    Time frame: Up to 152 weeks

  17. Overall Survival (OS)

    OS defined as the time from randomization until the date of death due to any cause.

    Time frame: Up to 152 weeks

  18. Percentage of Participants With AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs were coded using the standard Medical Dictionary for Regulatory Activities (MedDRA).

    Time frame: Up to 152 weeks

  19. Percentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Any AEs

    Percentage of participants requiring dose reduction, dose interruption/delay, permanent treatment discontinuation due to any AEs were presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs were coded using the standard MedDRA.

    Time frame: Up to 152 weeks

  20. Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline

    Blood samples were collected for the analysis of hematology parameters. The parameters were graded according to CTCAE grades. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases in grade 1/2/3 to a grade of 4 are presented.

    Time frame: Up to 152 weeks

  21. Number of Participants With Worst-Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline

    Blood samples were collected for the analysis of clinical chemistry parameters. The parameters were graded according to CTCAE grades. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases in grade 1/2/3 to a grade of 4 are presented.

    Time frame: Up to 152 weeks

  22. Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

    Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and up to 152 weeks

  23. Titers of ADAs Against Belantamab Mafodotin

    Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

    Time frame: Up to 152 weeks

  24. Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC)

    Plasma samples were collected for PK analysis for belantamab mafodotin antibody-drug conjugate (ADC).

    Time frame: Cycle(C)1 Day(D) 1 Pre-dose, End of Infusion (EOI), Start of Infusion (SOI) + 2 hours (H); C1D2 SOI+24H; C1D4; C1D8-15

  25. Concentration at 21 Days for Belantamab Mafodotin ADC

    Plasma samples were collected for PK analysis for belantamab mafodotin ADC.

    Time frame: At 21 days

  26. Average Concentration Over 21 Days (Cavg) for Belantamab Mafodotin ADC

    Plasma samples were collected for PK analysis for belantamab mafodotin ADC.

    Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15, D21

  27. Area Under the Concentration-time Curve (AUC) (0-504h) of Belantamab Mafodotin ADC

    Plasma samples were collected to determine the area under the concentration-time curve (AUC) (0-504h) of Belantamab mafodotin ADC.

    Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15, D21

  28. Half-life (t1/2) of Belantamab Mafodotin ADC

    Plasma samples were collected for PK analysis of Belantamab mafodotin ADC

    Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15

  29. Clearance (CL) for Belantamab Mafodotin ADC

    Plasma samples were collected for PK analysis for belantamab mafodotin ADC.

    Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15

  30. Steady-state Volume of Distribution (Vss) for Belantamab Mafodotin ADC

    Plasma samples were collected for PK analysis for belantamab mafodotin ADC.

    Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15

07

Results

Posted Oct 7, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Started4040404017
Safety3940394017
Pharmacokinetic3841394017
Completed107897
Not completed3033323110
Withdrew: Death232325215
Withdrew: Lost to follow-up12020
Withdrew: Physician decision11200
Withdrew: Withdrawal by subject45363
Withdrew: Ongoing at the time of analysis12222

Outcome measures

PrimaryPercentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale

The KVA scale is based on the evaluation of corneal changes using slit lamp examination. This scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.

Time frame:
Up to 29.5 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale
Percentage of participantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W
Percentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale64404438
SecondaryNumber of Participants With Corneal Events up to Week 16

The number of participants with corneal events were assessed using KVA scale. The KVA scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.

Time frame:
Up to week 16
Reported as:
Count of participants · Participants
Number of Participants With Corneal Events up to Week 16
ParticipantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Number of Participants With Corneal Events up to Week 162625232412
SecondaryIncidence Rate of Corneal Events by Grade (KVA Scale)

Incidence rate of corneal events is defined as the percentage of participants with corneal events by grade according to the KVA scale. The KVA scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.

Time frame:
Up to 152 weeks
Reported as:
Number · Percentage of participants
Incidence Rate of Corneal Events by Grade (KVA Scale)
Percentage of participantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Grade 13107102
Grade 2104563
Grade 31591196
Grade 403102
SecondaryExposure Adjusted Incidence Rate of Corneal Events as Per CTCAE Grade

Exposure adjusted incidence rate of corneal events is defined as the number of participants with corneal events divided by the total exposure time for all participants at risk in the treatment group. Incidence rate for corneal events was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity. The number of participants with Grades 3,4, and 5 are presented.

Time frame:
Up to 152 weeks
Reported as:
Number · Events per 100 patient years
Exposure Adjusted Incidence Rate of Corneal Events as Per CTCAE Grade
Events per 100 patient yearsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Grade 342403
Grade 400000
Grade 500000
SecondaryMedian Duration of All the Dose Delays

Median duration of dose delays is defined as the median duration in time of all the dose delays in the respective treatment group. Duration of delays is defined as period from the expected start date of dose to actual start date of current dose.

Time frame:
Up to 152 weeks
Reported as:
Median · Days
Median Duration of All the Dose Delays
DaysArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Median Duration of All the Dose Delays39.0 (16 to 144)18.0 (4 to 125)51.0 (18 to 163)60.0 (34 to 103)59.0 (25 to 88)
SecondaryPercentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Corneal Events

The percentage of participants that required dose reduction, dose interruption/delay, permanent treatment discontinuation due to corneal events were evaluated using KVA Scale. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.

Time frame:
Up to 152 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Corneal Events
Percentage of participantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Dose Reduction3128262335
Dose Interruption/Delay5935283329
Permanent Treatment Discontinuation03006
SecondaryCumulative Incidence of Grade 2 or Above Corneal Events (KVA Scale)

Cumulative incidence of Grade 2 or above corneal events is defined as the percentage of corneal events of Grade 2 or above, as assessed using the KVA scale, within a specific time interval. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.

Time frame:
At 3 months, 6 months, 9 months and 12 months
Reported as:
Number · Percentage of events
Cumulative Incidence of Grade 2 or Above Corneal Events (KVA Scale)
Percentage of eventsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
At 3 months5932363353
At 6 months6437413859
At 9 months6440413859
At 12 months6440443859
SecondaryToxicity Index (TI)

Toxicity Index is a composite score derived from the severity grades of adverse events (AEs) reported during the study, based on the Common Terminology Criteria for Adverse Events (CTCAE). A participant's score is calculated as a function of the ordered toxicity grades, represented in descending order by sequence, on a scale of 0-6, where 0 represents no toxicity and 6 represents the highest toxicity. CTCAE grades are defined as follows: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe or medically significant but not immediately life-threatening), Grade 4 (Life-threatening consequences), and Grade 5 (Death related to AE). Higher grades indicate greater toxicity severity.

Time frame:
Up to 152 weeks
Reported as:
Mean · Score on scale
Toxicity Index (TI)
Score on scaleArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Toxicity Index (TI)3.68 ± 1.0783.83 ± 1.0173.87 ± 1.0923.43 ± 1.0313.64 ± 0.892
SecondaryDuration of Corneal Events of Grade 2 or Above

Duration of corneal events is defined for each participant as the sum of duration of all the corneal AEs. The duration is defined as time from onset of any corneal events (KVA scale) of Grade 2 or above to the first time resolution to baseline, Grade 1 or below. It required at least one day gap between the resolution of all events from first occurrence to the onset of next occurrence.

Time frame:
Up to 152 weeks
Reported as:
Median · Days
Duration of Corneal Events of Grade 2 or Above
DaysArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Duration of Corneal Events of Grade 2 or Above63.0 (22 to 296)67.5 (13 to 233)46.5 (20 to 162)53.5 (20 to 148)44.0 (21 to 274)
SecondaryPercentage of Time on Study With Grade 2 or Above Corneal Events

It is defined as the percentage of time that a participant has corneal events out of the total time that a participant is on the study. Time with corneal events is defined as time from onset of any corneal events (KVA scale) of Grade 2 or above to the first-time resolution to baseline, Grade 1 or below.

Time frame:
Up to 152 weeks
Reported as:
Median · Percentage of Time
Percentage of Time on Study With Grade 2 or Above Corneal Events
Percentage of TimeArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Percentage of Time on Study With Grade 2 or Above Corneal Events23.27 (0.5 to 76.7)24.86 (5.1 to 69.1)18.99 (0.4 to 78.1)23.67 (5.5 to 85.6)35.63 (3.9 to 61.6)
SecondaryNumber of Participants With Change in Best Corrected Visual Acuity Test (BCVA) Scores

Change in BCVA is defined as change in logarithm of the minimum angle of resolution (logMAR) units compared with baseline or the first visit after the cataract surgery. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any change from baseline categories is presented for right and left eyes. No change/improved vision is defined as a change from baseline \<0.1; a possible worsened vision is defined as a change from baseline \>=0.1 to \<=0.3; a definite worsened vision is defined as a change from baseline \>0.3 logMAR score. Improvement in BCVA is represented by a reduction in logMAR score from baseline, while worsening in BCVA is represented by an increase in logMAR score from baseline.

Time frame:
Baseline (Day 1) and up to 152 weeks
Reported as:
Count of participants · Participants
Number of Participants With Change in Best Corrected Visual Acuity Test (BCVA) Scores
ParticipantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Left Eye — No change162019278
Left Eye — Possible worsened vision23311
Left Eye — Definite worsened vision41112
Right Eye — No change1618212710
Right Eye — Possible worsened vision45221
Right Eye — Definite worsened vision11000
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

Time frame:
Up to 152 weeks
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Objective Response Rate (ORR)33 (18.6 to 49.1)25 (12.7 to 41.2)28 (14.6 to 43.9)25 (12.7 to 41.2)18 (3.8 to 43.4)
SecondaryPercentage of Participants With a Confirmed VGPR or Better (i.e., VGPR, CR, and sCR)

Percentage of participants with a confirmed VGPR or better defined as percentage of participant with confirmed VGPR, CR, and sCR, according to the 2016 IMWG response criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h.

Time frame:
Up to 152 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With a Confirmed VGPR or Better (i.e., VGPR, CR, and sCR)
Percentage of participantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Percentage of Participants With a Confirmed VGPR or Better (i.e., VGPR, CR, and sCR)25 (12.7 to 41.2)18 (7.3 to 32.8)8 (1.6 to 20.4)15 (5.7 to 29.8)18 (3.8 to 43.4)
SecondaryTime to Response (TTR)

TTR defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better), according to the 2016 IMWG response criteria. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

Time frame:
Up to 152 weeks
Reported as:
Median · Months
Time to Response (TTR)
MonthsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Time to Response (TTR)0.8 (0.7 to 1.4)1.1 (0.7 to 2.1)0.7 (0.7 to 0.9)0.8 (0.7 to 2.2)1.5 (0.8 to NA)
SecondaryDuration of Response (DoR)

DoR defined as the time from first documented evidence of PR or better until disease progression (PD) among responders according to the 2016 IMWG response criteria or death due to any cause. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).

Time frame:
Up to 152 weeks
Reported as:
Median · Months
Duration of Response (DoR)
MonthsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Duration of Response (DoR)15.9 (4.9 to 21.4)22.1 (4.2 to NA)6.2 (2.1 to 20.7)7.8 (2.8 to 13.3)15.9 (NA to NA)
SecondaryTime to Progression (TTP)

TTP defined as the time from randomization until the earliest date of documented PD or death due to PD, according to the 2016 IMWG response criteria. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).

Time frame:
Up to 152 weeks
Reported as:
Median · Months
Time to Progression (TTP)
MonthsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Time to Progression (TTP)6.0 (2.8 to 10.4)2.1 (1.0 to 9.1)2.8 (1.7 to 4.2)2.7 (1.9 to 5.6)2.9 (0.8 to 17.3)
SecondaryProgression Free Survival (PFS)

PFS defined as the time from randomization until the earliest date of documented PD, according to the 2016 IMWG response criteria, or death due to any cause. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).

Time frame:
Up to 152 weeks
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Progression Free Survival (PFS)5.7 (2.8 to 9.0)2.1 (1.0 to 3.6)2.8 (1.4 to 3.5)2.7 (1.9 to 4.2)2.8 (0.8 to 17.3)
SecondaryOverall Survival (OS)

OS defined as the time from randomization until the date of death due to any cause.

Time frame:
Up to 152 weeks
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Overall Survival (OS)20.9 (8.1 to NA)15.0 (7.6 to 20.1)13.5 (7.5 to 21.2)14.5 (7.7 to NA)NA (4.8 to NA)
SecondaryPercentage of Participants With AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs were coded using the standard Medical Dictionary for Regulatory Activities (MedDRA).

Time frame:
Up to 152 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs
Percentage of participantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Percentage of Participants With AEs100100100100100
SecondaryPercentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Any AEs

Percentage of participants requiring dose reduction, dose interruption/delay, permanent treatment discontinuation due to any AEs were presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs were coded using the standard MedDRA.

Time frame:
Up to 152 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Any AEs
Percentage of participantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Dose Reduction8135518
Dose Interruption/Delay3123131035
Permanent Treatment Discontinuation10810518
SecondaryNumber of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline

Blood samples were collected for the analysis of hematology parameters. The parameters were graded according to CTCAE grades. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases in grade 1/2/3 to a grade of 4 are presented.

Time frame:
Up to 152 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline
ParticipantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Eosinophilia, Increase to Grades 1 to 431210
Eosinophilia, Increase to Grades 2 to 400000
Eosinophilia, Increase to Grades 3 to 400000
Anemia, Increase to Grades 1 to 4171520156
Anemia, Increase to Grades 2 to 4161417145
Anemia, Increase to Grades 3 to 41091194
Hemoglobin increased, Increase to Grades 1 to 411000
Hemoglobin increased, Increase to Grades 2 to 400000
Hemoglobin increased, Increase to Grades 3 to 400000
Leukocytosis, Increase to Grades 1 to 420000
Leukocytosis, Increase to Grades 2 to 420000
Leukocytosis, Increase to Grades 3 to 420000
White blood cell decreased, Increase to Grades 1 to 4221718199
White blood cell decreased, Increase to Grades 2 to 417131396
White blood cell decreased, Increase to Grades 3 to 497564
Lymphocyte count decreased, Increase to Grades 1 to 418131566
Lymphocyte count decreased, Increase to Grades 2 to 4117953
Lymphocyte count decreased, Increase to Grades 3 to 464441
Lymphocyte count increased, Increase to Grades 1 to 422340
Lymphocyte count increased, Increase to Grades 2 to 422340
Lymphocyte count increased, Increase to Grades 3 to 422130
Neutrophil count decreased, Increase to Grades 1 to 415121295
Neutrophil count decreased, Increase to Grades 2 to 4107674
Neutrophil count decreased, Increase to Grades 3 to 454234
Platelet count decreased, Increase to Grades 1 to 4243023217
Platelet count decreased, Increase to Grades 2 to 4152012135
Platelet count decreased, Increase to Grades 3 to 49131094
SecondaryNumber of Participants With Worst-Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline

Blood samples were collected for the analysis of clinical chemistry parameters. The parameters were graded according to CTCAE grades. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases in grade 1/2/3 to a grade of 4 are presented.

Time frame:
Up to 152 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst-Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline
ParticipantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Alanine aminotransferase increased, Increase to Grades 1 to 49141292
Alanine aminotransferase increased, Increase to Grades 2 to 423110
Alanine aminotransferase increased, Increase to Grades 3 to 410100
Hypoalbuminemia, Increase to Grades 1 to 4191514137
Hypoalbuminemia, Increase to Grades 2 to 4691162
Hypoalbuminemia, Increase to Grades 3 to 412110
Alkaline phosphatase increased, Increase to Grades 1 to 41015893
Alkaline phosphatase increased, Increase to Grades 2 to 412110
Alkaline phosphatase increased, Increase to Grades 3 to 400010
Aspartate aminotransferase increased, Increase to Grades 1 to 4202322143
Aspartate aminotransferase increased, Increase to Grades 2 to 443210
Aspartate aminotransferase increased, Increase to Grades 3 to 410100
Blood bilirubin increased, Increase to Grades 1 to 444433
Blood bilirubin increased, Increase to Grades 2 to 420001
Blood bilirubin increased, Increase to Grades 3 to 400000
Hypercalcemia, Increase to Grades 1 to 4141315124
Hypercalcemia, Increase to Grades 2 to 432531
Hypercalcemia, Increase to Grades 3 to 431221
Hypocalcemia, Increase to Grades 1 to 412168106
Hypocalcemia, Increase to Grades 2 to 434321
Hypocalcemia, Increase to Grades 3 to 413110
CPK increased, Increase to Grades 1 to 4118562
CPK increased, Increase to Grades 2 to 453100
CPK increased, Increase to Grades 3 to 421000
Creatinine increased, Increase to Grades 1 to 4141818157
Creatinine increased, Increase to Grades 2 to 469672
Creatinine increased, Increase to Grades 3 to 400101
Chronic Kidney Disease, Increase to Grades 1 to 468884
Chronic Kidney Disease, Increase to Grades 2 to 466884
Chronic Kidney Disease, Increase to Grades 3 to 433132
GGT increased, Increase to Grades 1 to 417161695
GGT increased, Increase to Grades 2 to 4107371
GGT increased, Increase to Grades 3 to 423130
Blood lactate dehydrogenase increased, Increase to Grades 1 to 4201919156
Blood lactate dehydrogenase increased, Increase to Grades 2 to 400000
Blood lactate dehydrogenase increased, Increase to Grades 3 to 400000
Hypermagnesemia, Increase to Grades 1 to 423320
Hypermagnesemia, Increase to Grades 2 to 402210
Hypermagnesemia, Increase to Grades 3 to 402210
Hypomagnesemia, Increase to Grades 1 to 473582
Hypomagnesemia, Increase to Grades 2 to 410010
Hypomagnesemia, Increase to Grades 3 to 410000
Hyperkalemia, Increase to Grades 1 to 446712
Hyperkalemia, Increase to Grades 2 to 412200
Hyperkalemia, Increase to Grades 3 to 411100
Hypernatremia, Increase to Grades 1 to 444353
Hypernatremia, Increase to Grades 2 to 412011
Hypernatremia, Increase to Grades 3 to 412011
SecondaryNumber of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and up to 152 weeks
Reported as:
Count of participants · Participants
Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
ParticipantsArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin00000
SecondaryTiters of ADAs Against Belantamab Mafodotin

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

Time frame:
Up to 152 weeks

No measurements were reported for this outcome.

SecondaryMaximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC)

Plasma samples were collected for PK analysis for belantamab mafodotin antibody-drug conjugate (ADC).

Time frame:
Cycle(C)1 Day(D) 1 Pre-dose, End of Infusion (EOI), Start of Infusion (SOI) + 2 hours (H); C1D2 SOI+24H; C1D4; C1D8-15
Reported as:
Geometric mean · Microgram/ millilitre (ug/mL)
Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC)
Microgram/ millilitre (ug/mL)Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC)44.8 ± 22.833.1 ± 23.242.1 ± 24.733.1 ± 18.334.1 ± 26.8
SecondaryConcentration at 21 Days for Belantamab Mafodotin ADC

Plasma samples were collected for PK analysis for belantamab mafodotin ADC.

Time frame:
At 21 days
Reported as:
Geometric mean · ug/mL
Concentration at 21 Days for Belantamab Mafodotin ADC
ug/mLArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Concentration at 21 Days for Belantamab Mafodotin ADC2.28 ± 56.71.5 ± 62.41.94 ± 69.31.69 ± 50.21.53 ± 62.1
SecondaryAverage Concentration Over 21 Days (Cavg) for Belantamab Mafodotin ADC

Plasma samples were collected for PK analysis for belantamab mafodotin ADC.

Time frame:
C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15, D21
Reported as:
Geometric mean · ug/mL
Average Concentration Over 21 Days (Cavg) for Belantamab Mafodotin ADC
ug/mLArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Average Concentration Over 21 Days (Cavg) for Belantamab Mafodotin ADC8.4 ± 32.25.98 ± 34.67.71 ± 38.66.3 ± 27.16.11 ± 40.6
SecondaryArea Under the Concentration-time Curve (AUC) (0-504h) of Belantamab Mafodotin ADC

Plasma samples were collected to determine the area under the concentration-time curve (AUC) (0-504h) of Belantamab mafodotin ADC.

Time frame:
C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15, D21
Reported as:
Geometric mean · micrograms* hour/ millilitre (ug*h/mL)
Area Under the Concentration-time Curve (AUC) (0-504h) of Belantamab Mafodotin ADC
micrograms* hour/ millilitre (ug*h/mL)Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Area Under the Concentration-time Curve (AUC) (0-504h) of Belantamab Mafodotin ADC4233 ± 32.23013 ± 34.63886 ± 38.63173 ± 27.13079 ± 40.6
SecondaryHalf-life (t1/2) of Belantamab Mafodotin ADC

Plasma samples were collected for PK analysis of Belantamab mafodotin ADC

Time frame:
C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
Reported as:
Geometric mean · Days
Half-life (t1/2) of Belantamab Mafodotin ADC
DaysArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Half-life (t1/2) of Belantamab Mafodotin ADC13 ± 30.512 ± 32.112 ± 4012 ± 34.213 ± 41.3
SecondaryClearance (CL) for Belantamab Mafodotin ADC

Plasma samples were collected for PK analysis for belantamab mafodotin ADC.

Time frame:
C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
Reported as:
Geometric mean · Liter/ days
Clearance (CL) for Belantamab Mafodotin ADC
Liter/ daysArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Clearance (CL) for Belantamab Mafodotin ADC0.8 ± 38.30.83 ± 57.10.84 ± 47.70.74 ± 53.30.86 ± 59.7
SecondarySteady-state Volume of Distribution (Vss) for Belantamab Mafodotin ADC

Plasma samples were collected for PK analysis for belantamab mafodotin ADC.

Time frame:
C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
Reported as:
Geometric mean · Liter
Steady-state Volume of Distribution (Vss) for Belantamab Mafodotin ADC
LiterArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Steady-state Volume of Distribution (Vss) for Belantamab Mafodotin ADC10.0 ± 19.69.3 ± 26.49.4 ± 26.98.9 ± 25.410.0 ± 16.1

Adverse events

Collected over All-cause mortality, Serious adverse events (SAEs) and non-serious AEs (Non SAEs) were collected up to 152 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)23/40 (57.5%)17/39 (43.6%)38/39 (97.4%)
Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W23/40 (57.5%)17/40 (42.5%)36/40 (90%)
Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)25/40 (62.5%)21/39 (53.8%)36/39 (92.3%)
Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W21/40 (52.5%)16/40 (40%)40/40 (100%)
Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)5/17 (29.4%)4/17 (23.5%)16/17 (94.1%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
ThrombocytopeniaBlood and lymphatic system disorders2/394/402/392/401/17
PneumoniaInfections and infestations2/393/403/392/401/17
SepsisInfections and infestations3/391/400/390/400/17
GingivitisInfections and infestations0/390/400/390/401/17
Upper respiratory tract infectionInfections and infestations0/390/400/391/401/17
Febrile neutropeniaBlood and lymphatic system disorders0/390/401/390/401/17
PyrexiaGeneral disorders0/390/400/390/401/17
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/390/400/390/401/17
Gingival bleedingGastrointestinal disorders0/390/400/390/401/17
Respiratory distressRespiratory, thoracic and mediastinal disorders0/390/400/390/401/17
Most frequent other events
Showing 10 of 100
Most frequent other events
EventArm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
Vision blurredEye disorders16/3912/4018/3911/409/17
Dry eyeEye disorders15/3912/4012/3912/408/17
ThrombocytopeniaBlood and lymphatic system disorders11/3917/4013/3910/404/17
AnaemiaBlood and lymphatic system disorders9/3912/4012/3915/404/17
Eye irritationEye disorders11/399/4011/3911/405/17
PhotophobiaEye disorders8/3910/4010/393/405/17
Foreign body sensation in eyesEye disorders7/397/4011/395/403/17
NeutropeniaBlood and lymphatic system disorders3/398/403/397/404/17
Eye painEye disorders9/392/406/394/403/17
NauseaGastrointestinal disorders3/393/408/393/400/17

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)Total
Mean66.6 ± 10.3663.0 ± 9.0263.7 ± 9.9265.4 ± 8.8767.1 ± 10.4264.9 ± 9.66
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)Total
Female19211916883
Male21192124994
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)Arm B: Belantamab Mafodotin 1.9 mg/kg Q3WArm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)Arm D: Belantamab Mafodotin 1.9 mg/kg Q6WArm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)Total
Hispanic or Latino139126646
Not Hispanic or Latino2731283411131
08

Study locations

77 sites
  • GSK Investigational Site
    West Palm Beach, Florida 33401, United States
  • GSK Investigational Site
    Kansas City, Missouri 64114, United States
  • GSK Investigational Site
    New York, New York 10065, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37404, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Houston, Texas 77090, United States
  • GSK Investigational Site
    Buenos Aires, C1181ACH, Argentina
  • GSK Investigational Site
    Capital Federal, C1426ANZ, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, 1414, Argentina
  • GSK Investigational Site
    Pilar, B1629AHJ, Argentina
  • GSK Investigational Site
    Rosario, S2002, Argentina
  • GSK Investigational Site
    Liverpool, New South Wales 2170, Australia
  • GSK Investigational Site
    Newcastle, New South Wales 2298, Australia
  • GSK Investigational Site
    Woodville, South Australia 5011, Australia
  • GSK Investigational Site
    East Melbourne, Victoria 3002, Australia
  • GSK Investigational Site
    Joinville, 89201-260, Brazil
  • GSK Investigational Site
    Porto Alegre, 90850-170, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 22271-110, Brazil
  • GSK Investigational Site
    Salvador, 41253-190, Brazil
  • GSK Investigational Site
    São Paulo, 01236-030, Brazil
  • GSK Investigational Site
    São Paulo, 04537-080, Brazil
  • GSK Investigational Site
    Montreal, Quebec H4J 1C5, Canada
  • GSK Investigational Site
    Avignon, 84902, France
  • GSK Investigational Site
    Nice, 06189, France
  • GSK Investigational Site
    Orléans, 45100, France
  • GSK Investigational Site
    Cottbus, 03048, Germany
  • GSK Investigational Site
    Dresden, 01307, Germany
  • GSK Investigational Site
    Greifswald, 17475, Germany
  • GSK Investigational Site
    Hamburg, 22763, Germany
  • GSK Investigational Site
    Athens, 106 76, Greece
  • GSK Investigational Site
    Athens, 11528, Greece
  • GSK Investigational Site
    Athens, 12462, Greece
  • GSK Investigational Site
    Rio Patras, 26504, Greece
  • GSK Investigational Site
    Dublin, 8, Ireland
  • GSK Investigational Site
    Dublin, D09 V2N0, Ireland
  • GSK Investigational Site
    Alessandria, 15121, Italy
  • GSK Investigational Site
    Ascoli Piceno, 63100, Italy
  • GSK Investigational Site
    Ferrara, 44124, Italy
  • GSK Investigational Site
    Genova, 16132, Italy
  • GSK Investigational Site
    Meldola FC, 47014, Italy
  • GSK Investigational Site
    Reggio Emilia, 42123, Italy
  • GSK Investigational Site
    Rimini, 47900, Italy
  • GSK Investigational Site
    Mexico City, 03100, Mexico
  • GSK Investigational Site
    Mexico City, 03720, Mexico
  • GSK Investigational Site
    Bydgoszcz, 85-168, Poland
  • GSK Investigational Site
    Gdansk, 80-214, Poland
  • GSK Investigational Site
    Katowice, 40-519, Poland
  • GSK Investigational Site
    Lublin, 20-081, Poland
  • GSK Investigational Site
    Poznan, 60-569, Poland
  • GSK Investigational Site
    Torun, 87-100, Poland
  • GSK Investigational Site
    Warsaw, 02-781, Poland
  • GSK Investigational Site
    Wałbrzych, 58-309, Poland
  • GSK Investigational Site
    Wroclaw, 50-367, Poland
  • GSK Investigational Site
    Hwasun, 58128, South Korea
  • GSK Investigational Site
    Pusan, 49241, South Korea
  • GSK Investigational Site
    Seoul, 03080, South Korea
  • GSK Investigational Site
    Seoul, 06591, South Korea
  • GSK Investigational Site
    Albacete, 02006, Spain
  • GSK Investigational Site
    Barcelona, 08026, Spain
  • GSK Investigational Site
    Córdoba, 140044, Spain
  • GSK Investigational Site
    Girona, 17007, Spain
  • GSK Investigational Site
    Oviedo, 33011, Spain
  • GSK Investigational Site
    Terrassa - Barcelona, 08221, Spain
  • GSK Investigational Site
    Valencia, 46010, Spain
  • GSK Investigational Site
    Bern, 3010, Switzerland
  • GSK Investigational Site
    Taichung, 404, Taiwan
  • GSK Investigational Site
    Taichung, 40705, Taiwan
  • GSK Investigational Site
    Tainan, 704, Taiwan
  • GSK Investigational Site
    Taipei, 100, Taiwan
  • GSK Investigational Site
    Taipei, 112, Taiwan
  • GSK Investigational Site
    Bangkok, 10210, Thailand
  • GSK Investigational Site
    Bangkok, 10330, Thailand
  • GSK Investigational Site
    Chiang Mai, 50200, Thailand
  • GSK Investigational Site
    Khon Kaen, 40002, Thailand
  • GSK Investigational Site
    Leicester, LE1 5WW, United Kingdom
  • GSK Investigational Site
    London, W12 0HS, United Kingdom
  • GSK Investigational Site
    Stoke-on-Trent, ST4 6QG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Aug 2024, 29 months.

Results were first posted in Oct 2025, 1 year 1 month after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 29 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2021
First posted
Oct 1, 2021
StartActual
Mar 3, 2022
Primary completionActual
Aug 19, 2024
CompletionActual
Feb 10, 2026
Results first posted
Oct 7, 2025
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05064358
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Mar 3, 2022
Primary completion
Aug 19, 2024
Completion
Feb 10, 2026
Results posted
Oct 7, 2025
Last update
May 5, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab mafodotin

Start the discussion